Abbott Laboratories (NYSE:
Wells Fargo Securities Healthcare Broker Conference Call
September 7, 2016 08:45 ET
Executives
Brian Yoor - Senior Vice President and Chief Financial Officer
Analysts
Larry Biegelsen - Wells Fargo
Larry Biegelsen
I am Larry Biegelsen, the medical device analyst at Wells Fargo and it\xe2\x80\x99s my pleasure to introduce Abbott this morning to kick off our 2016 healthcare conference. With me, we have Brian Yoor, Senior Vice President and CFO and Mike Comilla, who is the Senior Director of Investor Relations. In terms of format, it\xe2\x80\x99s fireside chat, I will ask a series of questions and people in the audience who have question raise your hand and we will do our best to get everybody\xe2\x80\x99s questions answered. Before starting, I have been asked to read a statement. So before we start, Abbott would like me to read this disclosure.
I would like to remind you that this discussion will include forward-looking statements and that actual plans and results could differ materially from those expressed or implied in the forward-looking statement. The factors that could cause actual results to differ are discussed in Abbott 2015 annual report as well as other filings Abbott has made and will make with the SEC. As you will recall, Abbott issued a press release on April 28, 2016 and now it\xe2\x80\x99s been the transaction with St. Jude. Please refer to pages 5 and 6 of that release for additional important information about Abbott, St. Jude and related matters.
So Brian, let\xe2\x80\x99s just start with the elephant in the room Alere and St. Jude. You know, I understand you are limited in what you can say but I am sure investors would love to hear you latest thoughts on each of those deals in light of the Alere lawsuit and the St. Jude cyber security issues raised by Muddy Waters.
Brian Yoor
Okay, Larry. Thank you, thanks for having me today. Let me start with Alere. I think the company has spoken on behalf of what our position is with Alere. Those facts are well documented, they are out there in the public domain. I understand and we understand this can cause uncertainty but rest assure and we talked about this, it will play out in time. The one important thing that I noted around the Alere that we always said this is that we like their products, we like the markets and the channels that they are in and believe that they would be a great opportunistic position for us with what is already a strong performing diagnostics business. Our diagnostic business from a core position is arguably one of our strongest top to bottom performing business and as a leader and we can talk more about that when we go through the questions on innovation there. With respect to St. Jude, again I pointed to what they have been saying publicly, I think something we just put out this morning on their position. I can\xe2\x80\x99t speak personally to that. You have to reach out to St. Jude for that. I think also so you can point to the other third party assessments that have been done with respect to Muddy Waters etcetera. We continue to work very collaboratively with St. Jude to advance the transaction. The integration is going very well. The management teams are very collaborative working together and we just look forward to creating again the premier medical device company that we want to with this combination of companies between Abbott and St. Jude with a leading position clearly in the cardiovascular neuromodular space.
Larry Biegelsen
Thanks. And with regard to the St. Jude deal are you still on track to close the deal by yearend and what are the remaining outstanding events before deal close?
Brian Yoor
Yes, we are still on track to close the deal. The management team as I have said are working very well together. You know, there has been a second request that\xe2\x80\x99s out there from the FCC. We will have to let that process unfold. I mean that\xe2\x80\x99s not uncommon with the transaction of this size, but what we have really because if two very complementary companies coming together so there is nothing that would cause me to say having a concern that we are not on track here and we expect to continue to close this by the end of the year.
Larry Biegelsen
And St. Jude\xe2\x80\x99s results in the second quarter was in line with their guidance of about 2% pro forma growth, so far it seems like there hasn\xe2\x80\x99t been any disruption from the deal. How confident are you that we won\xe2\x80\x99t see disruptions from the integration?
Brian Yoor
Yes, no it\xe2\x80\x99s good to see the stabilization Larry, and their performance, if you look at their results, they had very strong international results and also very strong results in what we know to be the high growth areas that we are interested in as well be that in atrial fibrillation in their space as they participate in the elbod [ph] space with hartnate [ph] and also in the neuromodulation space. So these high growth areas will continue to manifest themselves. We expect that to continue as you move through to completing this acquisition and become one company and then also we know that we want to see that stabilization in the CRM business op. They have an MRI safe claim that they are working towards and that should play out as we exit 2016 move into 2017 but clearly they have shown a track record that where they have this claim of an MRI safe label in Europe and Japan that they have been otherwise able to stabilize share. You know broadly speaking and this important to note, St. Jude participates in a weighted average market that\xe2\x80\x99s growing call it 3% to 4% and so not uncommon with the market that Abbott participants in and so as a company combined with a stronger foundation together in our approach to the market, we would see that going forward that the combined companies would have inline growth that\xe2\x80\x99s very \xe2\x80\x93 to mention to that what you are seeing Abbott today.
Larry Biegelsen
How quickly do you think the St. Jude business could get back to that kind of market growth with mid single digit growth?
Brian Yoor
I say we are little conservative for maybe what the analyst had. I think the analyst had like 5%, 6% out of the gates, you know we are a little bit more realistic and how we use into that, so I think you know that our that over the course you know how we ramped it up.
Larry Biegelsen
Okay. And I wanted to transition to 2016 trends but maybe we can scan the audience to see if there are any questions on the transaction. If not, I will move forward and ask about the underlying Abbott business. So we are roughly three quarters of the year through \xe2\x80\x93 three quarters of the way through 2016, you know you had a very strong first half of the year. Could you give us sense of the state of the business at Abbott, how does that compare to the outlook at the start of the year and what you see in emerging markets which are still about 50% of your sales?
Brian Yoor
Yes, we are very pleased with our first half performance. I think if you look at it on underlying normalized basis for all the moving parts, our topline at Abbott has been growing around 6% and so we are off to a good start. If you recall, in the first quarter, given that we have seen a little bit of easing around what we have seen for foreign exchange coupled with the performance of our businesses, we raised our initial guidance by about four pennies and so we still remain on track to achieve that which we put out as a range in the first quarter. If you look at the businesses, you know we have solid performance across all of our business through the first half. Diagnostics continues to grow in that 5% to 6% range. Nutrition, again if you take out some of the things to normalize with the countries that we\xe2\x80\x99ve exited, they are in that same range.
EPD has been a great standout this year, I mean we have seen them growing in the high single digits sometime double digit range, so that growth we expect to continue in our branded generics business and also very pleased about where we are in medical devices. We have seen a little bit of a step-up there. We are little bit ahead of our internal plans with respect to the vascular business overall. When you couple that with the ramp that we have going on with our FreeStyle Libre product with diabetes care internationally and some of the other things that we\xe2\x80\x99ve done with our Cadillac business with some of the some of the new lines that we\xe2\x80\x99ve launched, it\xe2\x80\x99s put forth a solid growth of around 6% underlying.
So I think we are well on track as we move through the area to achieve our objectives which again the range I think we put out is $2.19 to $2.29.
Larry Biegelsen
Yes, but in the first half of 2016, there were a couple of businesses such as international pediatric nutritional in U.S. core diagnostics which were below the recent historical trends, are there businesses such as those that you actually expect to improve in the second half?
Brian Yoor
Let me diagnostics first, that\'s just a comparator to last year. Again diagnostic\xe2\x80\x99s underlying growth is strong. As I mentioned, it\xe2\x80\x99s arguably one of our best performing divisions top to bottom. There was a situation last year where we had some sales on behalf of the competitor who couldn\xe2\x80\x99t supply. It was a just a comp issue Larry there. When you look at nutrition, I think Miles alluded to this on our second quarter call that you know we are little cautious about the Chinese pediatric nutrition market and I think you see all of those out there seeing the same thing. What I would classify China, it\xe2\x80\x99s a market in transition, still very attractive long term but there is a lot of also channel dynamics that happen very fast and consumer trends and behaviors that change really fast and that\xe2\x80\x99s what companies right now including ourselves are adapting to making the adjustments around.
We have a great portfolio. We are well positioned to compete in each of the segments and the various channels that are out there. But we have to let this play out and see how the market evolves. So I think it\xe2\x80\x99s a little bit in transition now. What\xe2\x80\x99s important for us and again happy to have this is that balance, okay. China, nutrition represents about 3% of Abbott sales, so we are not over indexed and as we are not in any business and that\xe2\x80\x99s always part of what we have been trying to do is to participate broadly. So we have a very healthy adult business, makes us a little bit unique in nutrition and we are also in many markets. So our performance in nutrition is performing well in South East Asia, Latin America countries, small albeit higher growth in the countries of Russia and India. So the long term prospects are there in good but we will just continue to watch and see how the China market continues to evolve on the pediatric side.
Larry Biegelsen
And vice-versa, are there markets in that where businesses in the first half that over performed your expectation where maybe there were one time benefits or you know the growth wasn\xe2\x80\x99t sustainable?
Brian Yoor
I don\xe2\x80\x99t see that. The only that we had in the first half was a true up if you will of a royally adjustment that even normalizing for that we have very strong growth in the second quarter and even normalizing for that you know our vascular business continues to be a little bit ahead of our internal plans which is positive for us even heading into this transaction where will bring this two companies together and even have a stronger foundation from which to compete.
Larry Biegelsen
That\xe2\x80\x99s helpful. Now I wanted to ask a question on capital allocation, just gaining room for hands, feel free if you have a question. So you are taking out a lot of new debt with the St. Jude deal. Can you talk about your capital allocation priorities after the deals you know pre St. Jude, I think your debt-to-EBITDA was about two times with St. Jude we estimate it will be closer to four times excluding Alere. So what your target debt-to-EBITDA ratio post the St. Jude deal and how quickly can you get there?
Brian Yoor
Sure. We have been very public about this and again under the assumption of both transactions closing which are financing contemplated, we publicly stated that out of the gates we would be at a 4.5 times ratio of debt to EBITDA that we would implement a de-leveraging plan to bring that down to at least 3.5 by 2018 so that\xe2\x80\x99s all out there in the public domain, you know, so we will continue to focus on our cash flow. I would say, you know, the dividend has always been an important part of our identity but we publicly stated that the pace of growth may be moderate a bit. With respect to share buybacks, we have seen as we have been very active over the few years sometimes doing $1 billion and $2 billion worth of share buybacks, I think it will be safe to assume that that would otherwise be deployed towards our deleveraging plans. And then finally, I think, I could set the expectation, we can set the expectation that there won\xe2\x80\x99t be any significant M&A until we get down to a level that we are comfortable with over the longer term in terms of deleveraging and those commitment that we publicly stated and committed to by 2018.
Larry Biegelsen
That\xe2\x80\x99s helpful. I wanted to ask about the outlook beyond 2016, we think about, you know, the first step of this year you grew about 6% organically, I think the guidance for this year is mid single digit organic growth? So obviously, you are not going to provide guidance until January but how would you like the investment community think about next year in terms of the puts the takes on your top and bottom line you know underlying growth?
Brian Yoor
Sure. Well, I think I would start historically, you have seen this. Historically, we always strive to have that underlying growth of double digit. So I think if I look back over the past 10 years, we probably achieved that all but maybe one year and I think that year was 9.5. So you know that\xe2\x80\x99s always our starting point of what we would like to achieve, but you know I said back to say growth relative. When you look at 6% growth to your point of where we have been growing, we are very pleased with that type of growth especially when you look across the world and think about where GDP is at, we are in a low growth environment globally speaking, kind of a low inflationary environment, so I think 6% type of growth is very respectable. We have been in that range, so as a starting point we are very positive without that.
We are always going to continue true to expand margins. I mean, you have seen the company expand its margins very rapidly notably in a couple of our businesses, nutrition and diagnostics and that\xe2\x80\x99s not just happening in those business, it\xe2\x80\x99s happening elsewhere, it\xe2\x80\x99s happening in branded generics and other businesses. Sometimes it\xe2\x80\x99s mitigated or offset by the effect of exchange obviously but you know margin improvement for our businesses and for Abbott overall is just a part of our DNA. It\xe2\x80\x99s something that were expected due and always there has been a key priority, so while the pace of margin expansion underline may not be at the same cliff as what we have seen for diagnostics and nutrition, we will continue to work on efforts to improve those margins related businesses but at a more moderated pace.
We see opportunities in branded generics. I mean, we have been building out our mote to be leaders in those key markets that are attractive for a pair of branded generics company. But now with the scale with leverage with the acquisitions we made, we have a little bit more flexibility of what we might do from a network and an optimization of our supply chain to achieve improvements in a branded generics operating margins here over the coming years and then finally I would not note, we\xe2\x80\x99ve done a lot around our back office on the G&A component of Abbott. We are far along in through that process but there is still little bit more that we can do and focus on from the back office to take out otherwise non value added G&A to continue to have a level of underlying margin expansion that has been our identity and what we strive for over the past few years.
Larry Biegelsen
Just, that\xe2\x80\x99s helpful. Just to be clear the double digit growth that you mentioned earlier that was on the EPS side that you targeted.
Brian Yoor
That was on the EPS side.
Larry Biegelsen
And then on the 6% you are referring to is the topline.
Brian Yoor
The topline\xe2\x80\xa6
Larry Biegelsen
Growth that we have seen in the first half.
Brian Yoor
That\xe2\x80\x99s right.
Larry Biegelsen
Then if you were take\xe2\x80\xa6
Brian Yoor
Not a guidance but that\xe2\x80\x99s a frame of reference.
Larry Biegelsen
And one of the tailwinds you have next year is you don\xe2\x80\x99t have the Venezuela headwind which has been about 200 basis points this year. Any other kind of clicks and takes that we should be aware of when we think about 2017?
Brian Yoor
Yes, I think, talk about some of the, let\xe2\x80\x99s talk about tailwinds. You know as I look at it, I think we will continue to focus on emerging markets. I know that they have been under pressure from exchange the last few years totally acknowledge but if you look at our emerging market growth across Abbott quarter-after-quarter it\xe2\x80\x99s continuing to deliver double digit. So we are optimistic that on a tailwind perspective that trend of healthcare and healthcare penetration that is still very below the developed markets is going to continue. We also see a continued trend you know where consumers are participating in their healthcare in these markets and they are making choices about brand whether that is brand from a nutrition perspective or brand from a branded generics perspective. So the emerging markets will continue to be a nice tailwind for us given our presence and scale that we have across all of our businesses in emerging markets.
As I think about other tailwinds or things we are going to want to watch as we go through 2017 and into 2018 is the launch of our new diagnostics systems. We have been out there at AACC. We have I would call an unprecedented launch plans for system and solution that span the whole array of diagnostics from immunoassay to clinical chemistry to blood screening to hematology to point of care and then down the road, I would say molecular. We are really excited about this because we just don\xe2\x80\x99t see as comprehensive or as unified as an offering that\xe2\x80\x99s going to add value to the health systems and do so in a very cost competitive way for our customers and for us if you will in our penetration of the business.
I think, we are also going to watch FreeStyle Libre from an organic standpoint very excited about what this product has been able to do outside the U.S. Again I will use the word again. I think it has had an unprecedented uptick as you compare it to the patient\xe2\x80\x99s uptake of those adopted FreeStyle Libre and these are consumers. A different approach where we launch this as a consumer product in Europe and it continues to have a rapid uptick. We are working towards reimbursement now which will provide more demand for us and how we balance the demand consumer reimbursement. As you know Larry, we filed last year for a professional use device in the United States, so that\xe2\x80\x99s been about a year. Again, we can\xe2\x80\x99t totally predict timing but you know it\xe2\x80\x99s probably getting close and that\xe2\x80\x99s a smaller market in the U.S. but it\xe2\x80\x99s a great start to ultimately bringing FreeStyle Libre to the U.S. from a consumer proposition.
I can\xe2\x80\x99t speak specific about the timing. I will update you more as we move towards that. But those are some excited things for us that we have going on organically that we will watch in the next year. You know the things that we always watch externally Larry will be, you know, what are the rate policies that are going on in the United States, what that do within the for exchange rates. We clearly watch what\xe2\x80\x99s going on in China to the extend, it is big country outside the U.S. and we want to modulate what\xe2\x80\x99s going on from a GDP growth rate there and will.
So we are always watching these three factors and the point is there is always going to be some ebbs and flows in Abbott\xe2\x80\x99s portfolio the way we constructed but that\xe2\x80\x99s constructed with intent because I think what\xe2\x80\x99s good about, even I think back over the past few years, there is always an incident but the incidence we have been able to navigate because of our diversity and shots on goal that we have in these growth markets but our portfolio has been pretty resilient when you think about the situations that have been going on in the world whether it\xe2\x80\x99s political turmoil, or unrest in some counties, impeachments or Brexits but again that gets back through the investment thesis and proposition of where we\xe2\x80\x99re playing broadly to make sure we can weather some of those individual storms to deliver otherwise very competitive growth versus our competition.
Larry Biegelsen
I had a couple of follow-up questions on the new products. You mentioned just gaining room again to see if there are questions here. On the diagnostic side, the Alinity platform that\xe2\x80\x99s the new platform that you referred to a minute ago, so what are the key features and differentiators versus the competition and how should we think about the roll out of potential impact on the diagnostics business?
Brian Yoor
Sure. I think, again, I don\xe2\x80\x99t look at these as instruments or machines or just test or anything. These are solutions and that\xe2\x80\x99s what the Alinity was designed to come about by unity and alignment. I think the real \xe2\x80\x93 one of the key features, this is going to have a common look and feel if you are a lab operator whether you are working on an immunoassay clinical chemistry machine or having to switchover to hematology or blood screening machine. So there\xe2\x80\x99s a lot of commonality. Today, you go to a lab, you\xe2\x80\x99ll find, you know today an architect looks totally different from maybe what our Cell Dyn in hematology looks like. So that\xe2\x80\x99s one of the big features. You\xe2\x80\x99re going to definitely have a smaller footprint and if you think about space being important to the lab, you think about throughput per square foot being important to the lab, there is definitely a cost and efficiency here for our customers. First time, right results, less downtime and I want to say the wraparound and you saw those too, the first of the launches we had was a product AlinIQ and think about that as an app that almost allows you to have predictive analytics. It\xe2\x80\x99s allowing you to monitor your inventory levels within the lab, it\xe2\x80\x99s given you decision smart analytical tools and so we\xe2\x80\x99re going to be able to have these common user interfaces and be able to have connectivity in the way that the lab is going to be able to operate in a much more efficiency manner.
Larry Biegelsen
It\xe2\x80\x99s helpful. And the rollout?
Brian Yoor
Well, I think as we exit this year and into next year, you\xe2\x80\x99ll start to hear more noise about where we\xe2\x80\x99re at, where we were, natural to think we will roll out in Europe first. CE Mark would typically come first in diagnostics or med devices even now and then the U.S. would follow that a couple of years down the road.
Larry Biegelsen
Thanks. And then please go ahead, a question in the front here.
Q - Unidentified Analyst
[Question Inaudible]
Brian Yoor
As I mentioned earlier with Alere, our comments are out in the public domain. You can see our position on it and I know this might not be satisfactory to you but there is going to be some uncertainty, we\xe2\x80\x99ll have to let the process play out. But it\xe2\x80\x99s going to play out one way or another and when it does, we\xe2\x80\x99d be more in a position to talk to you about point of care going forward. We have a great point of care business that\xe2\x80\x99s been performing on the top line 7%, 8%, sometimes 9% growth. So we are a leader in that space. We have innovations going on there where we continue to work on what the roll out of the test will be on that and we see more rapid expansion there. It\xe2\x80\x99s actually when you look at diagnostics, one of our best performing teams in terms of an operating margin profile and as I mentioned \xe2\x80\x93 I mentioned earlier, I\xe2\x80\x99ll mention again. We like the product of Alere. We like the markets they are in, we like the channels and how they complement otherwise where Abbott is already strong and a leader but we\xe2\x80\x99re going to have to let the process play out as far as next steps.
Larry Biegelsen
Some of the other, on the medical device side, you are also launching a host of new products, you talked about Libre.
Brian Yoor
That\xe2\x80\x99s right.
Larry Biegelsen
A couple that you didn\xe2\x80\x99t talk about are Absorb, you just got approval for the United States. Symfony, we\xe2\x80\x99ve had really good feedback on Symfony from cataract surgeons in the United States, I think that\xe2\x80\x99s been a successful product.
Brian Yoor
Yes.
Larry Biegelsen
Outside the U.S. and MitraClip, even though it\xe2\x80\x99s not a new product, it\xe2\x80\x99s still kind of early in the launch in the United States and it\xe2\x80\x99s $300 million product growing pretty rapidly. Can you talk about the impact of those products on your device business?
Brian Yoor
Yes, let me take more time and thanks Larry for the question because I think it\xe2\x80\x99s important to stress the balance that we\xe2\x80\x99ve had of both organic success as well as I will say inorganic opportunity to come here and that plays out in our results. You mentioned Symfony. We\xe2\x80\x99ve been participating and playing and competing very well in what I\xe2\x80\x99ll call the higher end lenses that come with cataract surgery. Some people will call them the premium channel IOL, some will say presbyopia correcting IOLs. We\xe2\x80\x99ve continued to gain share in this space which if you look at the market overall, it\xe2\x80\x99s a smaller portion by volume versus the mono-focal lenses that you are familiar with. But it has been growing and it\xe2\x80\x99s a much greater proposition by value and that\xe2\x80\x99s where we\xe2\x80\x99ve be gaining share and having great success in the cataract business that has put this business to growing close to mid single-digit. Symfony is the lens that Larry is referring to. It had had great success in Europe and now, we\xe2\x80\x99ve brought eVersion [ph] to the U.S. and continue to roll that out as a value proposition for our customers. I\xe2\x80\x99ve already spoken at length about Libre but exciting for us what we\xe2\x80\x99re doing here internationally and even more exciting about the prospects of what it\xe2\x80\x99ll bring to our overall growth as we bring that ultimately to the U.S.
That switches me over to vascular and here, you have MitraClip which we\xe2\x80\x99ve very excited about. It was about $250 million in sales last year experiencing significant growth and we\xe2\x80\x99re seeing much of the same this year. We\xe2\x80\x99re seeing more uptake and adoption by the centers in the U.S. and also outside the U.S. and this is important foundation because it\xe2\x80\x99s the one of only kind of its device participate in what we believe is going to be a large part of the structural heart market over time when you think about the mitral valve space. So MitraClip continues to grow. It rates very similar to last year. I think, you\xe2\x80\x99re going to see great results when we move out through the end of this year there. Complementing that was an acquisition we made in a company called Tendyne and again, we\xe2\x80\x99re seeing great results year-to-date. A CE trial for that is underway and Tendyne has a product that will complement MitraClip in that it is a replacement product versus MitraClip today is a repair product. So I believe we\xe2\x80\x99re well positioned in structural heart in the mitral valve space with the performance of MitraClip and what\xe2\x80\x99s to come on Tendyne.
You know, Absorb is exciting for us because again it\xe2\x80\x99s the one and only kind of its device and really it becomes complementary to the portfolio itself. When you are approaching decision makers, you are going to find a population of people, physicians, centers who just want to have Absorb and so when you look at in totality with what it brings to your ability to go in and offer a value proposition to an IDN or a buying group that is exciting for us. We are seeing some nice capture of some accounts in our vascular business because while it might not be the mass \xe2\x80\x93 the majority of procedures by volume, it does not to the portfolio of selling. I think that matters most when you think about St. Jude too. We\xe2\x80\x99re just going to continue to broaden that foundation of what we have being the number one stent company combined with the number two CRM company which provides that rocker foundation but not to forget that you know, you have now that license to go after these higher growth areas and continue to build on the pipeline and St. Jude has an attractive pipeline and we continue to build on ours and look forward to creating like I said the premium medical device company.
Larry Biegelsen
Thanks. We got about a minute and a half left and we\xe2\x80\x99ve got a question in the back. Someone is coming around with a mic.
Unidentified Analyst
Two quick questions. Can you talk to us about how you feel about the sustainability of EPD growth because that\xe2\x80\x99s been pretty impressive this year and then also just remind us on the surgery case with St. Jude, is that going to be largely driven by cost or is there a sales force integration and cross sell synergy as well that we should expect on revenues?
Brian Yoor
First, with respect to brand generics, great question. They\xe2\x80\x99ve already seen to your point some of the things I talked about in terms of political unrest or certain segments where you might see from time-to-time pricing but it\xe2\x80\x99s usually small in nature. Branded generics, I see it as very sustainable. It\xe2\x80\x99s a very different market than what we sometimes get used to as true generics here in the United States or propitiatory and we are essentially, we look globally in emerging markets only. We\xe2\x80\x99re about that only company solely focused on branded generics in those key markets that have the prospects of growth because it\xe2\x80\x99s important to consumer that they are getting the brand and quality that they want and so we see that as sustainable, I see it sustainable too that consumers are going to be asked to participate in their healthcare just given the patient load and access to care that we have there, so great business.
With respect to the synergies on St. Jude, we talked about that. We expect revenue synergies. Those we\xe2\x80\x99ll build more over time. Think of those as about 25% of the total synergies we expected to achieve in the coming years and then we expected gross margin synergies where we have shown again the ability as Abbott and we\xe2\x80\x99ll do again with St. Jude to find those network opportunities and the supply chain to improve gross margin, those were another 25% and then finally, you have just the basic G&A synergies where you are going after the elimination of redundancies there. What will happen as the synergies ramp to the target we had of about 500 million, it will happen in a liner fashion but it\xe2\x80\x99s more likely that you\xe2\x80\x99ll see expense synergies more heavily weighted on the front-end with revenue synergies building as we move out through the three years.
Larry Biegelsen
Perfect. So we\xe2\x80\x99re about a minute over. So we\xe2\x80\x99ll conclude. Brian and Mike, thank you very much for coming out today.
Brian Yoor
Thank you.
Larry Biegelsen
Thanks, everybody.
Copyright policy: 
THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY\'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY\'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY\'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.
If you have any additional questions about our online transcripts, please contact us at: 
